Afatinib Combined with Bevacizumab in the Treatment of Patients with Non-Small Cell Lung Cancer Harboring EGFR G719X, S768I or L861Q/P Mutations

Xiang Han, Yunhong You, Xiuhui Guo, Youxin Ji, Keke Nie · 2024

Read Afatinib Combined with Bevacizumab in the Treatment of Patients with Non-Small Cell Lung Cancer Harboring EGFR G719X, S768I or L861Q/P Mutations by Xiang Han, Yunhong You, Xiuhui Guo, Youxin Ji, Keke Nie (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11606169.txt.

Description

Xiang Han and colleagues reviewed records for a small group of lung cancer patients whose tumors carried uncommon mutations in a growth receptor gene. Standard targeted pills work less predictably for these rare variants than for the common ones. Writing in twenty twenty-four, the team gathered Chinese patients treated at first line with targeted therapy between twenty seventeen and twenty twenty-one. The regimen paired the pill afatinib with bevacizumab, a drug that blocks blood vessel growth. Response, survival, and side effects were collected from the charts.

More than half of the patients responded to treatment. Typical time before the cancer grew again was about eleven months, and typical overall survival was close to three years. Some patients gained a resistance mutation that opens other drug options. Side effects were mild to moderate, including skin problems on hands and feet, high blood pressure, and protein in the urine.

Catalog record

CREATORXiang Han, Yunhong You, Xiuhui Guo, Youxin Ji, Keke Nie
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE17 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11606169

Browse the full library · About the Tower of Babel